C4 Therapeutics (CCCC) Competitors $2.35 +0.02 (+0.86%) Closing price 04:00 PM EasternExtended Trading$2.35 0.00 (-0.21%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CCCC vs. REPL, EOLS, PHAT, KROS, RLAY, BCAX, TLRY, ORGO, XNCR, and MRVIShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Replimune Group (REPL), Evolus (EOLS), Phathom Pharmaceuticals (PHAT), Keros Therapeutics (KROS), Relay Therapeutics (RLAY), Bicara Therapeutics (BCAX), Tilray Brands (TLRY), Organogenesis (ORGO), Xencor (XNCR), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. Its Competitors Replimune Group Evolus Phathom Pharmaceuticals Keros Therapeutics Relay Therapeutics Bicara Therapeutics Tilray Brands Organogenesis Xencor Maravai LifeSciences Replimune Group (NASDAQ:REPL) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Is REPL or CCCC more profitable? Replimune Group has a net margin of 0.00% compared to C4 Therapeutics' net margin of -325.88%. C4 Therapeutics' return on equity of -53.91% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -69.34% -52.81% C4 Therapeutics -325.88%-53.91%-33.26% Which has more risk and volatility, REPL or CCCC? Replimune Group has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.97, meaning that its share price is 197% more volatile than the S&P 500. Which has higher earnings and valuation, REPL or CCCC? C4 Therapeutics has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$247.30M-$3.24-1.65C4 Therapeutics$35.58M4.70-$105.32M-$1.58-1.49 Do analysts recommend REPL or CCCC? Replimune Group currently has a consensus price target of $7.67, suggesting a potential upside of 43.30%. C4 Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 240.43%. Given C4 Therapeutics' higher possible upside, analysts clearly believe C4 Therapeutics is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 1 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.33C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do insiders and institutionals hold more shares of REPL or CCCC? 92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by company insiders. Comparatively, 8.7% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to REPL or CCCC? In the previous week, Replimune Group had 31 more articles in the media than C4 Therapeutics. MarketBeat recorded 38 mentions for Replimune Group and 7 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.18 beat Replimune Group's score of -0.05 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 1 Very Positive mention(s) 4 Positive mention(s) 27 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral C4 Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryC4 Therapeutics beats Replimune Group on 10 of the 15 factors compared between the two stocks. Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.83M$3.10B$5.62B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-1.497.1521.9024.64Price / Sales4.70356.34464.89116.36Price / CashN/A43.0338.2159.48Price / Book0.968.608.826.15Net Income-$105.32M-$54.65M$3.25B$265.06M7 Day Performance-8.91%5.43%4.05%2.80%1 Month Performance-1.26%6.75%4.32%1.68%1 Year Performance-58.55%31.59%36.25%29.59% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics2.1441 of 5 stars$2.35+0.9%$8.00+240.4%-59.1%$165.83M$35.58M-1.49150Earnings ReportAnalyst RevisionGap UpREPLReplimune Group4.4741 of 5 stars$5.71-24.9%$7.67+34.3%-47.6%$591.34MN/A-1.86210Trending NewsEarnings ReportShort Interest ↑EOLSEvolus3.8905 of 5 stars$9.11-0.4%$23.75+160.7%-51.9%$589.95M$266.27M-10.24170PHATPhathom Pharmaceuticals3.0684 of 5 stars$8.64+3.5%$17.50+102.5%-14.0%$582.95M$55.25M-1.65110KROSKeros Therapeutics2.4511 of 5 stars$14.62+2.1%$30.56+109.0%-68.7%$581.61M$3.55M-81.22100Analyst RevisionRLAYRelay Therapeutics1.911 of 5 stars$3.65+8.6%$17.67+384.0%-47.9%$576.05M$10.01M-1.64330Earnings ReportBCAXBicara Therapeutics1.9976 of 5 stars$11.12+5.6%$31.86+186.5%N/A$574.27MN/A0.0032News CoverageEarnings ReportAnalyst ForecastTLRYTilray Brands2.3881 of 5 stars$0.61+6.9%$1.92+215.3%-33.0%$572.39M$821.31M-0.262,650Options VolumeGap DownORGOOrganogenesis4.2165 of 5 stars$4.60+2.0%$6.50+41.3%+84.6%$572.11M$482.04M-27.06950Earnings ReportXNCRXencor3.598 of 5 stars$7.95-0.4%$28.00+252.2%-51.7%$567.94M$110.49M-2.60280Analyst RevisionGap DownMRVIMaravai LifeSciences3.7033 of 5 stars$2.27+2.3%$6.64+192.5%-67.4%$565.34M$259.18M-1.99610News CoverageAnalyst ForecastGap Down Related Companies and Tools Related Companies Replimune Group Competitors Evolus Competitors Phathom Pharmaceuticals Competitors Keros Therapeutics Competitors Relay Therapeutics Competitors Bicara Therapeutics Competitors Tilray Brands Competitors Organogenesis Competitors Xencor Competitors Maravai LifeSciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CCCC) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access